Pfizer and Tris Pharma agreed to a $41.5 million settlement with Texas over claims they manipulated quality-control testing for children’s ADHD drug Quillivant XR to keep it Medicaid-eligible. Pfizer denied wrongdoing and said its review found no safety impact, while Tris did not comment. The case stemmed from a whistleblower complaint by a former Tris technology chief.
